The FDA and REMS

In July 2012, the US Food and Drug Administration released a risk evaluation and mitigation strategy for extended release pain medications. How will this REMS affect patients in pain and the physicians who treat them?

Lynn Webster, MD, is president elect of the American Academy of Pain Medicine, and he discusses REMS and pain in this edition of The Bioethics Channel with Lorell LaBoube.

Link: FDA opioid safety plan focuses on physician education, Christine S. Moyer, American Medical News, July 23, 2012